Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocytosis. Cancer Res; 77(6); 1261-70. ©2017 AACR.

[1]  A. Órfão,et al.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature , 2016, Oncotarget.

[2]  P. Jeandel,et al.  Midostaurin in Advanced Systemic Mastocytosis. , 2016, The New England journal of medicine.

[3]  F. Awan,et al.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. , 2016, The New England journal of medicine.

[4]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[5]  J. Merker,et al.  Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia , 2016, Leukemia.

[6]  G. Superti-Furga,et al.  Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth , 2016, Leukemia.

[7]  A. Órfão,et al.  KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. , 2015, Blood.

[8]  Massimo Triggiani,et al.  Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. , 2016, The Journal of allergy and clinical immunology.

[9]  A. Órfão,et al.  Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. , 2016, The Journal of allergy and clinical immunology.

[10]  T. Haferlach,et al.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.

[11]  S. Schoenberg,et al.  Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis , 2016, Leukemia.

[12]  G. Stefanzl,et al.  Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. , 2015, Blood.

[13]  K. Sotlar,et al.  Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. , 2015, The Journal of allergy and clinical immunology.

[14]  C. Heybeli.  Mast Cells, Mastocytosis, and Related Disorders. , 2015, The New England journal of medicine.

[15]  B. Grosbois,et al.  Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. , 2015, Blood.

[16]  A. Órfão,et al.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications , 2015, Modern Pathology.

[17]  L. Ayadi,et al.  An unusual tumour of the lung. , 2015, Pathologica.

[18]  M. Triggiani,et al.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis , 2015, Leukemia.

[19]  T. Haferlach,et al.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event , 2015, Leukemia.

[20]  H. Pehamberger,et al.  Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. , 2014, American journal of blood research.

[21]  T. Rülicke,et al.  Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia , 2014 .

[22]  L. Pagano,et al.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. T. Olalla Saad,et al.  Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. , 2014, Leukemia research.

[24]  M. Triggiani,et al.  Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis , 2014, Allergy.

[25]  M. Triggiani,et al.  Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  G. Bandara,et al.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. , 2014, The Journal of allergy and clinical immunology.

[27]  P. Valent,et al.  The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease , 2014, Allergy.

[28]  Florent Langenfeld,et al.  Molecular defects in mastocytosis: KIT and beyond KIT. , 2014, Immunology and allergy clinics of North America.

[29]  A. Órfão,et al.  Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. , 2014, The Journal of allergy and clinical immunology.

[30]  G. Stefanzl,et al.  The pan‐Bcl‐2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells , 2014, Journal of leukocyte biology.

[31]  A. Marx,et al.  Mast cell sarcoma mimicking metastatic colon carcinoma , 2014, Annals of Hematology.

[32]  A. Órfão,et al.  CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis , 2013, Histopathology.

[33]  F. Awan,et al.  Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial , 2013 .

[34]  C. E. Pedreira,et al.  Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome , 2013, PloS one.

[35]  A. Kohlmann,et al.  Comprehensive mutational profiling in advanced systemic mastocytosis. , 2013, Blood.

[36]  A. Pardanani.  How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). , 2013, Blood.

[37]  A. Marx,et al.  The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis , 2013, Annals of Hematology.

[38]  S. T. Olalla Saad,et al.  Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis , 2012, PloS one.

[39]  C. Bindslev‐Jensen,et al.  Circulating KIT D816V mutation‐positive non‐mast cells in peripheral blood are characteristic of indolent systemic mastocytosis , 2012, European journal of haematology.

[40]  A. Órfão,et al.  An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis , 2012, Leukemia.

[41]  A. Órfão,et al.  Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Chlebowski.  Obesity and breast cancer outcome: adding to the evidence. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Triggiani,et al.  Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal , 2011, International Archives of Allergy and Immunology.

[44]  C. Akin,et al.  Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. , 2011, Leukemia research.

[45]  G. Superti-Furga,et al.  KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. , 2011, Blood.

[46]  K. Sotlar,et al.  Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms , 2011, Leukemia & lymphoma.

[47]  K. Sotlar,et al.  Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis , 2011, Modern Pathology.

[48]  H. Vestergaard,et al.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. , 2011, The Journal of molecular diagnostics : JMD.

[49]  M. Chilosi,et al.  Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis , 2011, Haematologica.

[50]  D. Maric,et al.  Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis , 2011, Haematologica.

[51]  P. Valent,et al.  How I treat patients with advanced systemic mastocytosis. , 2010, Blood.

[52]  H. Pehamberger,et al.  In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. , 2010, Experimental hematology.

[53]  P. Valent,et al.  Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives , 2010, Expert review of hematology.

[54]  L. Thomas,et al.  Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. , 2010, The Journal of investigative dermatology.

[55]  A. Tefferi,et al.  WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.

[56]  A. Parafioriti,et al.  Osteoporosis with vertebral fractures in young males, due to bone marrow mastocytosis: a report of two cases. , 2010, Clinical and experimental rheumatology.

[57]  A. Tefferi,et al.  Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine , 2009, American journal of hematology.

[58]  P. Valent,et al.  Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[59]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[60]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[61]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[62]  D. Gilliland,et al.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.

[63]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[64]  R. Moriggl,et al.  Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens1 , 2008, The Journal of Immunology.

[65]  F. Sim,et al.  Mastocytosis (Mast Cell Disease) , 2008 .

[66]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[67]  K. Sotlar,et al.  Mastocytosis: State of the Art , 2007, Pathobiology.

[68]  T. Lister,et al.  A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. , 2006, Leukemia research.

[69]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[70]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[71]  Cem Akin,et al.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. , 2004, Blood.

[72]  A. Órfão,et al.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.

[73]  M. Uffmann,et al.  Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. , 2004, Leukemia research.

[74]  H. Kluin-Nelemans,et al.  Cladribine therapy for systemic mastocytosis. , 2003, Blood.

[75]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[76]  J. Bennett,et al.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. , 2003, Leukemia research.

[77]  V. Eclache,et al.  Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patients , 2002, British journal of haematology.

[78]  A. Órfão,et al.  Mastocytosis: current concepts in diagnosis and treatment , 2002, Annals of Hematology.

[79]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[80]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[81]  P. Valent,et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. , 2001, Leukemia research.

[82]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[83]  R. Parwaresch,et al.  Temporary Response of Localized Intracranial Mast Cell Sarcoma to Combination Chemotherapy , 2001, Journal of pediatric hematology/oncology.

[84]  A. Tefferi,et al.  Treatment of systemic mast-cell disease with cladribine. , 2001, The New England journal of medicine.

[85]  H. Griesser,et al.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia , 2000, Molecular pathology : MP.

[86]  L. Schwartz,et al.  Serum tryptase and the laboratory diagnosis of systemic mastocytosis. , 2000, Hematology/oncology clinics of North America.

[87]  K. Lennert,et al.  Diagnostic value of immunostaining for tryptase in patients with mastocytosis. , 1998, The American journal of surgical pathology.

[88]  A. Órfão,et al.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. , 1998, Blood.

[89]  D. Metcalfe,et al.  Treatment of three patients with systemic mastocytosis with interferon alpha-2b. , 1996, Leukemia & lymphoma.

[90]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[91]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[92]  H. Kluin-Nelemans,et al.  Response to interferon alfa-2b in a patient with systemic mastocytosis. , 1992, The New England journal of medicine.

[93]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[94]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[95]  K. Lennert,et al.  Mast cell sarcoma of the larynx. , 1986, Journal of clinical pathology.

[96]  K. Lennert,et al.  Tissue mast cells in health and disease. , 1985, Pathology, research and practice.

[97]  K. Lennert,et al.  Mast cells and mast cell neoplasia: a review * , 1979, Histopathology.

[98]  R. Caplan.  The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. , 1963, Archives of dermatology.

[99]  E. B. Helwig,et al.  Solitary mastocytosis (urticaria pigmentosa). , 1961, Archives of dermatology.

[100]  L. Chargin,et al.  Urticaria pigmentosa appearing as a solitary nodular lesion. , 1954, A.M.A. archives of dermatology and syphilology.